Literature DB >> 25623677

Evaluation of patients' perceptions of mesh usage in female pelvic medicine and reconstructive surgery.

Christopher F Tenggardjaja1, Courtenay K Moore2, Sandip P Vasavada2, Jianbo Li3, Howard B Goldman2.   

Abstract

OBJECTIVE: To evaluate if new patients presenting to a female pelvic medicine and reconstructive surgery clinic are aware of the US Food and Drug Administration (FDA) announcement regarding transvaginal mesh placement for pelvic organ prolapse repair and do they believe there is a mesh recall.
METHODS: A voluntary anonymous 25-question survey was administered to new-clinic patients. Participants were aged at least 18 years and had either urinary incontinence or pelvic organ prolapse. Appropriate statistical tests were performed for continuous and categorical variables. Logistic regression was used for univariate and multivariable analysis. Significance was considered for P values <.05.
RESULTS: Two hundred fourteen surveys were included for final analysis. Of the 214 patients, 157 (73.4%) had urinary incontinence as their sole presentation. Of 204 patients, 126 (61.8%) were aware the FDA-released information regarding mesh use in transvaginal surgery, and 88 of 169 (52%) believed there is a "recall" on mesh being used for transvaginal surgery. Of 156 patients, 108 (69.2%) listed television as a source of information. On multivariable analysis, television as a source was significantly associated with awareness of the FDA announcement (odds ratio, 7.12; 95% confidence interval, 2.69-18.84; P = .0001) and belief in a "recall" (odds ratio, 3.01; 95% confidence interval, 1.28-7.06; P = .01).
CONCLUSION: Although almost 2 of 3 participants were aware of the FDA announcement, more than half falsely believed there was a recall. Television was significantly associated with both awareness of the FDA announcement and belief in a recall suggesting patients derive most of their perceptions from the television.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25623677     DOI: 10.1016/j.urology.2014.08.058

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Association of Attorney Advertising and FDA Action with Prescription Claims: A Time Series Segmented Regression Analysis.

Authors:  Elizabeth C Tippett; Brian K Chen
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

Review 2.  Making surgery safer through adequate communication with the stakeholders: vaginal slings.

Authors:  Sandra Elmer; Janelle Brennan; Rebecca Mathieson; Briony Norris; Marcus Carey; Caroline Dowling
Journal:  World J Urol       Date:  2019-07-04       Impact factor: 4.226

3.  Rate of Pelvic Organ Prolapse Surgery Among Privately Insured Women in the United States, 2010-2013.

Authors:  Anne G Sammarco; Carolyn W Swenson; Neil S Kamdar; Emily K Kobernik; John O L DeLancey; Brahmajee Nallamothu; Daniel M Morgan
Journal:  Obstet Gynecol       Date:  2018-03       Impact factor: 7.661

4.  The impact of the 2011 US Food and Drug Administration transvaginal mesh communication on utilization of synthetic mid-urethral sling procedures.

Authors:  Alexander A Berger; Jasmine Tan-Kim; Shawn A Menefee
Journal:  Int Urogynecol J       Date:  2020-11-18       Impact factor: 2.894

5.  Anatomical and functional outcomes after hysterectomy and bilateral sacrospinous ligament fixation for stage IV uterovaginal prolapse: a prospective case series.

Authors:  Tilemachos Kavvadias; Birgitt Schoenfisch; Sara Yvonne Brucker; Christl Reisenauer
Journal:  BMC Urol       Date:  2020-08-19       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.